CEFEPIME HYDROCHLORIDE

Post-LOE

cefepime hydrochloride

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Jul 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CEFEPIME HYDROCHLORIDE (cefepime hydrochloride) by Pfizer is [ see microbiology ( ]. Approved for the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa and 15 more indications. First approved in 2012.

Drug data last refreshed 19h ago

Mechanism of Action

[ See Microbiology ( ].

Indications (18)

the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae including cases associated with concurrent bacteremia

Worked on CEFEPIME HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.